We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Blood Filter Device Removes Circulating Tumor Cells in Pancreatic Cancer Patients

By HospiMedica International staff writers
Posted on 17 Jul 2023
Print article
Image: The OncoBind procedure is based on the Seraph 100 Microbind Affinity Blood Filter (Photo courtesy of ExThera)
Image: The OncoBind procedure is based on the Seraph 100 Microbind Affinity Blood Filter (Photo courtesy of ExThera)

Pancreatic Ductal Adenocarcinoma (PDAC), a type of pancreatic cancer, is predicted to be the second most common cause of cancer-related fatalities by 2030. Circulating Tumor Cells (CTCs), cancer cells that break away from a primary tumor and enter the bloodstream, are responsible for metastatic cancer. This form of cancer is often resistant to standard treatments such as chemotherapy, radiation, and immunotherapy, making it particularly difficult to treat. The presence of CTCs in blood correlates with the outcomes of metastatic cancer. Preliminary methods that extract CTCs from the bloodstream have shown promising results in animal trials, implying that reducing CTCs in the blood might slow or prevent metastasis. Now, an extracorporeal blood filter procedure can remove CTCs from the bloodstream of patients suffering from PDAC, offering an important tool for treating this lethal cancer with a low 5-year survival rate.

ExThera Medical’s (Martinez, CA, USA) OncoBind extracorporeal blood filter procedure, based on its Seraph 100 Microbind Affinity Blood Filter, has proven successful in removing metastatic circulating tumor cells in several in vitro models. As the patient's blood flows through the OncoBind Blood Filter, it passes over beads with receptors that imitate those on human cells that are targeted by pathogens and CTCs for attachment and colonization. The CTCs are then captured and adsorbed to the beads’ surface, effectively removing them from the bloodstream. Like the Seraph 100, the OncoBind system does not introduce anything foreign into the blood. OncoBind, similar to Seraph's adsorption media (the beads), represents a versatile platform that uses immobilized (chemically bonded) heparin due to its proven blood compatibility and its unique ability to bind CTCs. The U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application for ExThera’s OncoBind extracorporeal blood filter procedure.

“Seraph technology has an excellent safety record in more than 2,500 clinical treatments performed globally, of bacterial, viral, and fungal bloodstream infections,” said Bob Ward, Ph.D. (h)., NAE, the CEO & a founder of ExThera Medical. “We are pleased to begin an important new clinical trial, and ecstatic that FDA has approved our recent IDE application. If ExThera’s technology captures CTCs in the clinical setting, as it has in the laboratory, the potential is enormous, adding another much-needed tool to the arsenal for treating PDAC, a lethal cancer with a low 5-year survival rate.”

Related Links:
ExThera Medical 

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Plasma Freezer
iBF125-GX
New
Documentation System For Blood Banks
HettInfo II

Print article

Channels

Surgical Techniques

view channel
Image: (Left) An image of a 3D-printed material implanted in vivo for 4 weeks. (Right) A photo of coral (Photo courtesy of Dr Zhidao Xia and Jesus Cobaleda)

Revolutionary Coral-Inspired Material for Bone Repair Promotes Faster Healing

Bone defects caused by fractures, tumors, and non-healing injuries are major contributors to disability worldwide. Traditionally, doctors have used either a patient’s own bone (autograft) or donor bone... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.